Other treatment options used for human BCC patients include radiotherapy (which can also be used in the adjuvant setting), hedgehog pathway inhibitors (HHIs; >90% of sporadic BCCs have mutations in PTCH1 or SMO, allowing intrinsic activation of sonic hedgehog pathway), and immune checkpoint inhibitors such as the monoclonal PD-1 antibody, Cemiplimab-rwlc (FDA-approved for locally advanced BCC patients either previously treated with HHIs or for whom HHI use is not suitable) [29]. This evidence concerns the gene SMO and skin basal cell carcinoma.